Advanced Platforms for HIV Viral Load Monitoring announcement - CIMIT MAIN

Responsive Image
The FDA has approved the first rapid hepatitis C virus test for the U.S. market that can be used in patient care settings. The test, which was validated in part by the NIH RADx Tech program with funding from CDC, can provide results in about one hour, meaning patients with a positive test can begin treatment right away. We're honored to have been a part of the journey behind this important milestone! 

Learn more about this game changer for hepatitis C diagnosis >

Programs and Offerings

null Advanced Platforms for HIV Viral Load Monitoring announcement

New Funding Opportunity for HIV Viral Load Monitoring Point-of-Care Technologies

According to the FY 2021-2025 NIH Strategic Plan for HIV and HIV-Related Research coordinated by the NIH Office of AIDS Research (OAR), HIV persists as one of the world’s most serious public health, development, and economic challenges. Improved tools for HIV viral load monitoring at the point-of-care are needed, across the U.S. and the globe, that are sufficiently sensitive and simple to use so people with HIV can assess therapy effectiveness and the potential for transmission in their communities.

In collaboration with OAR and the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is soliciting proposals through the Rapid Acceleration of Diagnostics (RADx®) program, to accelerate the commercialization of innovative point-of-care HIV viral load testing platforms that facilitate monitoring antiretroviral therapy effectiveness and accurately assess potential for transmission.

Up to four selected organizations have the opportunity to receive:

  • Up to $1,000,000 in award funding
  • Wrap-around assistance from a national network of expert technical, clinical, manufacturing, and regulatory advisors
  • Support for technology de-risking, including third-party analytical and pre-clinical confirmation of device performance

The deadline for this opportunity has passed.

News and Events

Connect with Us

Our Lasting Impact

As an early pioneer in managing translational research, Cimit has directly supported over 1,200 innovator teams and reviewed or consulted on over 5,000 ideas since our founding in 1998.

We work collaboratively with healthtech innovators, entrepreneurs, and institutions to ultimately make a positive impact on patient care across the globe. We streamline pathways to progress through our efficient processes, established systems, and unparalleled market expertise.